I saw a post regarding this web blog today in the Geron YMB, Didn't think there was any news in this info regarding using Imetelstat for AML but maybe I'm missing something. So much going on with Imetelstat in & outside of the US but nothing official on an AML clinical trial, but suspect we are getting close.
http://www.issels.com/blog/2015/03/04/t ... aemia-aml/
Issels blog on imetelstat: Team Finds New Treatment for Acute Myeloid Leukaemia (AML)
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
huntingonthebluffs
- Posts: 154
- Joined: Wed Feb 24, 2016 12:00 am
-
Fishermangents
- Site Admin
- Posts: 529
- Joined: Thu Dec 03, 2015 3:39 pm
Re: Issels blog on imetelstat: Team Finds New Treatment for Acute Myeloid Leukaemia (AML)
Nice find! Although from March 2015, the article is becoming more actual every day that we are approaching the start of the AML trial this year. For those who don't want to click on links, here is the text:
Team Finds New Treatment for Acute Myeloid Leukaemia (AML)
Issels, Integrative Immuno-Oncology, Cancer Research news, 4 March 2015
Australian researchers have found that a drug called Imetelstat has the potential to fight and sometimes defeat blood cancer. Following the recent trials in Brisbane, the FDA has recently cleared the way for clinical trials in the United States.
How Does Imetelstat Kill Cancer Cells?
The medication works by manipulating a particular protein of the blood. Imetelstat effectively “turns off” a certain gene to prevent the formation of a protein called telomerase. Without that protein, the stem cells that become leukemia cells cannot be formed. Existing cancer cells begin to disappear. The news is especially exciting because chemotherapy has its lowest success rates with acute myeloid leukemia, or AML. Patients who have undergone unsuccessful chemotherapy for AML can potentially use Imetelstat to prolong life or possibly enter remission. For all AML patients, Imetelstat could be used as a follow-up treatment after chemotherapy to help prevent the cancer from returning.
What’s Next for Blood Cancer Medicine?
After the Australian team recently published their findings and made a presentation to the American Society of Hematology, interest in the treatment has further increased. The FDA had previously been concerned by a possible connection between Imetelstat and liver problems, but that issue has been ruled out. With that hurdle cleared, optimism is building for the breakthrough drug to succeed in human trials and find approval for all patients with AML.
link: http://www.issels.com/blog/2015/03/04/t ... aemia-aml/
Team Finds New Treatment for Acute Myeloid Leukaemia (AML)
Issels, Integrative Immuno-Oncology, Cancer Research news, 4 March 2015
Australian researchers have found that a drug called Imetelstat has the potential to fight and sometimes defeat blood cancer. Following the recent trials in Brisbane, the FDA has recently cleared the way for clinical trials in the United States.
How Does Imetelstat Kill Cancer Cells?
The medication works by manipulating a particular protein of the blood. Imetelstat effectively “turns off” a certain gene to prevent the formation of a protein called telomerase. Without that protein, the stem cells that become leukemia cells cannot be formed. Existing cancer cells begin to disappear. The news is especially exciting because chemotherapy has its lowest success rates with acute myeloid leukemia, or AML. Patients who have undergone unsuccessful chemotherapy for AML can potentially use Imetelstat to prolong life or possibly enter remission. For all AML patients, Imetelstat could be used as a follow-up treatment after chemotherapy to help prevent the cancer from returning.
What’s Next for Blood Cancer Medicine?
After the Australian team recently published their findings and made a presentation to the American Society of Hematology, interest in the treatment has further increased. The FDA had previously been concerned by a possible connection between Imetelstat and liver problems, but that issue has been ruled out. With that hurdle cleared, optimism is building for the breakthrough drug to succeed in human trials and find approval for all patients with AML.
link: http://www.issels.com/blog/2015/03/04/t ... aemia-aml/